|
1
|
Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes.
|
Cancer Immunol Immunother
|
2005
|
3.20
|
|
2
|
Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.
|
Drug Resist Updat
|
2007
|
2.21
|
|
3
|
Circulating tumour-derived microvesicles in plasma of gastric cancer patients.
|
Cancer Immunol Immunother
|
2009
|
1.55
|
|
4
|
Tumour-derived microvesicles modulate biological activity of human monocytes.
|
Immunol Lett
|
2007
|
1.43
|
|
5
|
Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis.
|
Antioxid Redox Signal
|
2013
|
1.15
|
|
6
|
Antitumor response of CD14+/CD16+ monocyte subpopulation.
|
Exp Hematol
|
2004
|
1.05
|
|
7
|
Expansion and differentiation of CD14+CD16(-) and CD14+ +CD16+ human monocyte subsets from cord blood CD34+ hematopoietic progenitors.
|
J Leukoc Biol
|
2007
|
0.93
|
|
8
|
Chemokine receptors and chemokine production by CD34+ stem cell-derived monocytes in response to cancer cells.
|
Anticancer Res
|
2012
|
0.82
|
|
9
|
Tumour-derived microvesicles contain interleukin-8 and modulate production of chemokines by human monocytes.
|
Anticancer Res
|
2011
|
0.81
|
|
10
|
Modulation of monocyte-tumour cell interactions by Mycobacterium vaccae.
|
Cancer Immunol Immunother
|
2004
|
0.80
|
|
11
|
Tumour-derived microvesicles (TMV) mimic the effect of tumour cells on monocyte subpopulations.
|
Anticancer Res
|
2010
|
0.78
|
|
12
|
Biological activity of dendritic cells generated from cord blood CD34+ hematopoietic progenitors in IL-7- and IL-13-conditioned cultures.
|
Arch Immunol Ther Exp (Warsz)
|
2009
|
0.75
|
|
13
|
Recognition of apoptotic cells by human peripheral blood monocytes does not alter their ability to phagocytize and kill Staphylococcus aureus.
|
Arch Immunol Ther Exp (Warsz)
|
2004
|
0.75
|